Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Equity Income (2024 - 2025)

Outlook Therapeutics (OTLK) has disclosed Equity Income for 2 consecutive years, with -$38634.0 as the latest value for Q4 2025.

  • Quarterly Equity Income fell 16.04% to -$38634.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$146346.0 through Dec 2025, changed N/A year-over-year, with the annual reading at -$141007.0 for FY2025, 39.97% down from the prior year.
  • Equity Income for Q4 2025 was -$38634.0 at Outlook Therapeutics, up from -$40419.0 in the prior quarter.
  • The five-year high for Equity Income was -$30884.0 in Q2 2025, with the low at -$40419.0 in Q3 2025.